KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Inventory (2016 - 2025)

Historic Inventory for Sarepta Therapeutics (SRPT) over the last 10 years, with Q3 2025 value amounting to $1.1 billion.

  • Sarepta Therapeutics' Inventory rose 9033.76% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 9033.76%. This contributed to the annual value of $750.0 million for FY2024, which is 13228.72% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Inventory is $1.1 billion, which was up 9033.76% from $994.0 million recorded in Q2 2025.
  • Sarepta Therapeutics' Inventory's 5-year high stood at $1.1 billion during Q3 2025, with a 5-year trough of $186.2 million in Q4 2021.
  • For the 5-year period, Sarepta Therapeutics' Inventory averaged around $421.1 million, with its median value being $268.8 million (2021).
  • As far as peak fluctuations go, Sarepta Therapeutics' Inventory crashed by 2332.21% in 2022, and later skyrocketed by 15203.65% in 2025.
  • Sarepta Therapeutics' Inventory (Quarter) stood at $186.2 million in 2021, then rose by 9.54% to $204.0 million in 2022, then soared by 58.29% to $322.9 million in 2023, then soared by 132.29% to $750.0 million in 2024, then soared by 43.63% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $994.0 million for Q2 2025, and $941.4 million during Q1 2025.